WAVE Life Sciences Ltd.
WVE
$6.73
-$0.06-0.88%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -68.67% | -67.73% | 44.00% | 59.27% | 64.46% |
Total Depreciation and Amortization | -5.90% | -8.72% | -10.77% | -10.89% | -8.98% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 34.16% | 18.21% | -3.86% | -37.90% | -43.07% |
Change in Net Operating Assets | -497.37% | -141.89% | -175.59% | -177.71% | 183.86% |
Cash from Operations | -677.24% | -616.26% | -1,088.39% | -5,699.87% | 84.79% |
Capital Expenditure | 15.87% | -25.44% | 16.28% | 36.48% | 18.07% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | 15.87% | -105.02% | -104.30% | -102.15% | 11.16% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 80.95% | 673.40% | 199.11% | 29.23% | 150.44% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 352,600.00% | -- | -- | -- |
Cash from Financing | 91.57% | 709.98% | 199.66% | 10.96% | 97.26% |
Foreign Exchange rate Adjustments | -45.26% | 138.98% | -25.24% | -2.07% | 54.76% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -9.03% | 297.68% | -138.04% | -118.78% | 280.30% |